ADC Therapeutics (ADCT) Net Cash Flow (2019 - 2023)
Historic Net Cash Flow for ADC Therapeutics (ADCT) over the last 5 years, with Q4 2023 value amounting to -$32.0 million.
- ADC Therapeutics' Net Cash Flow rose 7713.97% to -$32.0 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$48.0 million, marking a year-over-year increase of 6566.93%. This contributed to the annual value of -$27.6 million for FY2024, which is 4243.24% up from last year.
- Per ADC Therapeutics' latest filing, its Net Cash Flow stood at -$32.0 million for Q4 2023, which was up 7713.97% from -$37.0 million recorded in Q3 2023.
- Over the past 5 years, ADC Therapeutics' Net Cash Flow peaked at $36.9 million during Q2 2023, and registered a low of -$139.8 million during Q4 2022.
- In the last 5 years, ADC Therapeutics' Net Cash Flow had a median value of -$53951.0 in 2022 and averaged -$14.7 million.
- Data for ADC Therapeutics' Net Cash Flow shows a peak YoY increase of 6849910.29% (in 2023) and a maximum YoY decrease of 85901778.91% (in 2023) over the last 5 years.
- ADC Therapeutics' Net Cash Flow (Quarter) stood at -$34078.0 in 2019, then tumbled by 96372.8% to -$32.9 million in 2020, then surged by 99.81% to -$63679.0 in 2021, then plummeted by 219453.96% to -$139.8 million in 2022, then skyrocketed by 77.14% to -$32.0 million in 2023.
- Its Net Cash Flow stands at -$32.0 million for Q4 2023, versus -$37.0 million for Q3 2023 and $36.9 million for Q2 2023.